Addiction needs to be addressed by prevention and treatment, but policy makers need skin in the game too.
As With HIV, New York State Was Set to Lead the Nation to End Hepatitis C. But Why Haven’t the Recommendations Been Made Public?
Activist and member of the state task force Annette Gaudino would like the public to know.
IPERGAY scientists recommended that clinicians screen patients who request PrEP, as well as patients who are already using it, for a number of key HCV risk factors.
Jan. 16, 2020: Texting (and stigma support) vs. email for care retention; beyond-childhood health risks for HIV-exposed infants; HIV, cardiovascular risk, and cognitive impairment; direct-acting antiviral efficacy and prescription delays.
Jan. 9, 2020: Bone loss after HIV treatment initiation; aging and antiretroviral dosage; more U=U evidence for women; viral suppression and executive function.
The HIV services organization Housing Works implemented a hepatitis C treatment program in New York City, with very high completion rates.
Montreal scientists found that 88% of cannabis users had an undetectable viral load. This suggests that a very large majority of cannabis users did not have problems adhering to antiretroviral therapy.
Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
People in jail, who are often in the system for less time than those in prison, often receive little to no hepatitis C screening or treatment. One provider works to change this in Massachusetts.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.